Prescribing Trends of Glucose-Lowering Medications Near End of Life Among Adults With Type 2 Diabetes: A Cohort Study

Overview

Journal Diabetes Care

Specialty Endocrinology

Date 2025 Jan 2

PMID 39746144

Authors

Alexander Kutz

Dae Hyun Kim

Jun Liu

Medha N Munshi

Elisabetta Patorno

Affiliations

Soon will be listed here.

Abstract

Objective: To assess prescribing trends of glucose-lowering medications in the last year of life among older adults with type 2 diabetes (T2D) and explore whether frailty is associated with differential prescribing.

Research Design And Methods: In this observational cohort study of Medicare beneficiaries aged ≥67 years (2015-2019) with T2D, we assessed temporal trends in prescribing a glucose-lowering medication, stratified by frailty. The main outcome included glucose-lowering medication fills within 1 year of death.

Results: Among 975,407 community-dwelling Medicare beneficiaries with T2D, the use of glucose-lowering medications within 1 year of death slightly increased from 71.4% during the first 6-month period in 2015 to 72.9% (standardized mean difference [SMD] -0.03) during the second 6-month period in 2019. The most pronounced increase in use was observed for metformin (40.7% to 46.5%, SMD -0.12), whereas the largest decrease was observed for sulfonylureas (37.0% to 31.8%, SMD 0.11). Overall glucose-lowering medication use decreased from 66.1% in the 9 to 12 months before death to 60.8% in the last 4 months of life (SMD 0.11; P < 0.01), driven by reduced noninsulin medication use. The use of short-acting and long-acting insulin both increased near death, with frailer individuals more likely to receive insulin. Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists, although less common, became more frequent in more recent years.

Conclusions: The use of glucose-lowering medications declined in the last year of life, mainly due to reduced noninsulin use. Insulin use increased near death, particularly among frailer individuals, highlighting the need for careful end-of-life management.

References

Kirkman M, Jones Briscoe V, Clark N, Florez H, Haas L, Halter J . Diabetes in older adults. Diabetes Care. 2012; 35(12):2650-64. PMC: 3507610. DOI: 10.2337/dc12-1801. View

Abdelhafiz A, Sinclair A . Deintensification of hypoglycaemic medications-use of a systematic review approach to highlight safety concerns in older people with type 2 diabetes. J Diabetes Complications. 2017; 32(4):444-450. DOI: 10.1016/j.jdiacomp.2017.11.011. View

Butler D, Petterson S, Phillips R, Bazemore A . Measures of social deprivation that predict health care access and need within a rational area of primary care service delivery. Health Serv Res. 2012; 48(2 Pt 1):539-59. PMC: 3626349. DOI: 10.1111/j.1475-6773.2012.01449.x. View

Lipska K, Krumholz H, Soones T, Lee S . Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes. JAMA. 2016; 315(10):1034-45. PMC: 4823136. DOI: 10.1001/jama.2016.0299. View

Kim D, Glynn R, Avorn J, Lipsitz L, Rockwood K, Pawar A . Validation of a Claims-Based Frailty Index Against Physical Performance and Adverse Health Outcomes in the Health and Retirement Study. J Gerontol A Biol Sci Med Sci. 2018; 74(8):1271-1276. PMC: 6625579. DOI: 10.1093/gerona/gly197. View

Zullo A, Riester M, Hayes K, Munshi M, Berry S . Comparative safety of sulfonylureas among U.S. nursing home residents. J Am Geriatr Soc. 2022; 71(4):1047-1057. PMC: 10089954. DOI: 10.1111/jgs.18160. View

Murphy S, Xu J, Kochanek K, Curtin S, Arias E . Deaths: Final Data for 2015. Natl Vital Stat Rep. 2017; 66(6):1-75. View

Frank C, Weir E . Deprescribing for older patients. CMAJ. 2014; 186(18):1369-76. PMC: 4259770. DOI: 10.1503/cmaj.131873. View

Sinclair A, Abdelhafiz A, Dunning T, Izquierdo M, Rodriguez Manas L, Bourdel-Marchasson I . An International Position Statement on the Management of Frailty in Diabetes Mellitus: Summary of Recommendations 2017. J Frailty Aging. 2018; 7(1):10-20. DOI: 10.14283/jfa.2017.39. View

10.

Hamada S, Gulliford M . Drug prescribing during the last year of life in very old people with diabetes. Age Ageing. 2017; 46(1):147-151. PMC: 5388282. DOI: 10.1093/ageing/afw174. View

11.

Kutz A, Kim D, Wexler D, Liu J, Schneeweiss S, Glynn R . Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care. 2023; 46(11):2004-2014. PMC: 10620535. DOI: 10.2337/dc23-0671. View

12.

Khokhar B, Jette N, Metcalfe A, Cunningham C, Quan H, Kaplan G . Systematic review of validated case definitions for diabetes in ICD-9-coded and ICD-10-coded data in adult populations. BMJ Open. 2016; 6(8):e009952. PMC: 4985868. DOI: 10.1136/bmjopen-2015-009952. View

13.

Munshi M, Meneilly G, Rodriguez-Manas L, Close K, Conlin P, Cukierman-Yaffe T . Diabetes in ageing: pathways for developing the evidence base for clinical guidance. Lancet Diabetes Endocrinol. 2020; 8(10):855-867. PMC: 8223534. DOI: 10.1016/S2213-8587(20)30230-8. View

14.

Gerstein H, Miller M, Genuth S, Ismail-Beigi F, Buse J, Goff Jr D . Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011; 364(9):818-28. PMC: 4083508. DOI: 10.1056/NEJMoa1006524. View

15.

Scheen A . Careful use to minimize adverse events of oral antidiabetic medications in the elderly. Expert Opin Pharmacother. 2021; 22(16):2149-2165. DOI: 10.1080/14656566.2021.1912735. View

16.

Lipska K, Ross J, Miao Y, Shah N, Lee S, Steinman M . Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med. 2015; 175(3):356-62. PMC: 4426991. DOI: 10.1001/jamainternmed.2014.7345. View

17.

Gautam N, Bessette L, Pawar A, Levin R, Kim D . Updating International Classification of Diseases 9th Revision to 10th Revision of a Claims-Based Frailty Index. J Gerontol A Biol Sci Med Sci. 2020; 76(7):1316-1317. PMC: 8202141. DOI: 10.1093/gerona/glaa150. View

18.

Wu S, Chai S, Yang J, Cai T, Xu Y, Yang Z . Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Clin Ther. 2017; 39(9):1780-1789.e33. DOI: 10.1016/j.clinthera.2017.07.036. View

19.

Kim D, Patorno E, Pawar A, Lee H, Schneeweiss S, Glynn R . Measuring Frailty in Administrative Claims Data: Comparative Performance of Four Claims-Based Frailty Measures in the U.S. Medicare Data. J Gerontol A Biol Sci Med Sci. 2019; 75(6):1120-1125. PMC: 7243587. DOI: 10.1093/gerona/glz224. View

20.

Sison S, Shi S, Oh G, Jeong S, McCarthy E, Kim D . Claims-Based Frailty Index and Its Relationship With Commonly Used Clinical Frailty Measures. J Gerontol A Biol Sci Med Sci. 2024; 79(7). PMC: 11167486. DOI: 10.1093/gerona/glae094. View